Skip to main content
Top
Published in:

Open Access 03-01-2024 | COVID-19 | Original Article

Characteristics and prognosis of patients with COVID-19 and hematological diseases in Japan: a cross-sectional study

Authors: Daisuke Minakata, Tomoyuki Uchida, Aya Nakano, Ken Takase, Nodoka Tsukada, Hiroshi Kosugi, Eri Kawata, Takahiko Nakane, Hiroyuki Takahashi, Tomoyuki Endo, Satoshi Nishiwaki, Hideaki Fujiwara, Akiko M. Saito, Toshiki I. Saito, Koichi Akashi, Itaru Matsumura, Kinuko Mitani

Published in: International Journal of Hematology | Issue 2/2024

Login to get access

Abstract

The Japanese Society of Hematology performed an observational cross-sectional study to clarify the morbidity, prognosis, and prognostic factors in patients with COVID-19 with hematological diseases (HDs) in Japan. The study included patients with HDs who enrolled in our epidemiological survey and had a COVID-19 diagnosis and a verified outcome of up to 2 months. The primary endpoints were characteristics and short-term prognosis of COVID-19 in patients with HDs. A total of 367 patients from 68 institutes were enrolled over 1 year, and the collected data were analyzed. The median follow-up among survivors was 73 days (range, 1–639 days). The 60-day overall survival (OS) rate was 86.6%. In the multivariate analysis, albumin ≤ 3.3 g/dL and a need for oxygen were independently associated with inferior 60-day OS rates (hazard ratio [HR] 4.026, 95% confidence interval (CI) 1.954–8.294 and HR 14.55, 95% CI 3.378–62.64, respectively), whereas 60-day survival was significantly greater in patients with benign rather than malignant disease (HR 0.095, 95% CI 0.012–0.750). Together, these data suggest that intensive treatment may be necessary for patients with COVID-19 with malignant HDs who have low albumin levels and require oxygen at the time of diagnosis.
Appendix
Available only for authorised users
Literature
2.
go back to reference Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, et al. Clinical epidemiology of hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan: report of the COVID-19 Registry Japan. Clin Infect Dis. 2021;73:e3677–89.CrossRefPubMed Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, et al. Clinical epidemiology of hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan: report of the COVID-19 Registry Japan. Clin Infect Dis. 2021;73:e3677–89.CrossRefPubMed
4.
go back to reference Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020;4:5966–75.CrossRefPubMedPubMedCentral Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020;4:5966–75.CrossRefPubMedPubMedCentral
5.
go back to reference Malard F, Genthon A, Brissot E, van de Wyngaert Z, Marjanovic Z, Ikhlef S, et al. COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant. 2020;55:2180–4.CrossRefPubMedPubMedCentral Malard F, Genthon A, Brissot E, van de Wyngaert Z, Marjanovic Z, Ikhlef S, et al. COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant. 2020;55:2180–4.CrossRefPubMedPubMedCentral
6.
go back to reference Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, EPICOVIDEHA working group, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14:168.CrossRefPubMedPubMedCentral Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, EPICOVIDEHA working group, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14:168.CrossRefPubMedPubMedCentral
7.
go back to reference Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92.CrossRefPubMedPubMedCentral Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92.CrossRefPubMedPubMedCentral
8.
go back to reference Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, ITA-HEMA-COV Investigators, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737–45.CrossRefPubMedPubMedCentral Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, ITA-HEMA-COV Investigators, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737–45.CrossRefPubMedPubMedCentral
9.
go back to reference Martín-Moro F, Marquet J, Piris M, Michael BM, Sáez AJ, Corona M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020;190:e16–20.CrossRefPubMedPubMedCentral Martín-Moro F, Marquet J, Piris M, Michael BM, Sáez AJ, Corona M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020;190:e16–20.CrossRefPubMedPubMedCentral
10.
go back to reference Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033–40.CrossRefPubMed Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033–40.CrossRefPubMed
11.
go back to reference Horiuchi H, Morishita E, Urano T, Yokoyama K, Questionnaire-survey Joint Team on The COVID-19-related thrombosis. COVID-19-related thrombosis in japan: final report of a questionnaire-based survey in 2020. J Atheroscler Thromb. 2021;28:406–16.CrossRefPubMedPubMedCentral Horiuchi H, Morishita E, Urano T, Yokoyama K, Questionnaire-survey Joint Team on The COVID-19-related thrombosis. COVID-19-related thrombosis in japan: final report of a questionnaire-based survey in 2020. J Atheroscler Thromb. 2021;28:406–16.CrossRefPubMedPubMedCentral
12.
go back to reference Uchida T, Takagi Y, Mizuno A, Okamura H, Saito H, Ide S, et al. [Retrospective analysis of nosocomial COVID-19: a comparison between patients with hematological disorders and other diseases]. Rinsho Ketsueki. 2020;61:857–864. Uchida T, Takagi Y, Mizuno A, Okamura H, Saito H, Ide S, et al. [Retrospective analysis of nosocomial COVID-19: a comparison between patients with hematological disorders and other diseases]. Rinsho Ketsueki. 2020;61:857–864.
16.
go back to reference Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed
17.
go back to reference Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383:2586–8.CrossRefPubMed Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383:2586–8.CrossRefPubMed
18.
go back to reference Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, UK Coronavirus Cancer Monitoring Project Team, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21:1309–16 (Erratum in: Lancet Oncol. 2020 Sep 3).CrossRefPubMedPubMedCentral Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, UK Coronavirus Cancer Monitoring Project Team, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21:1309–16 (Erratum in: Lancet Oncol. 2020 Sep 3).CrossRefPubMedPubMedCentral
19.
go back to reference Jee J, Foote MB, Lumish M, Stonestrom AJ, Wills B, Narendra V, et al. Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol. 2020;38:3538–46.CrossRefPubMedPubMedCentral Jee J, Foote MB, Lumish M, Stonestrom AJ, Wills B, Narendra V, et al. Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol. 2020;38:3538–46.CrossRefPubMedPubMedCentral
20.
go back to reference Aziz M, Fatima R, Lee-Smith W, Assaly R. The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis. Crit Care. 2020;24(1):255.CrossRefPubMedPubMedCentral Aziz M, Fatima R, Lee-Smith W, Assaly R. The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis. Crit Care. 2020;24(1):255.CrossRefPubMedPubMedCentral
21.
go back to reference Kheir M, Saleem F, Wang C, Mann A, Chua J. Higher albumin levels on admission predict better prognosis in patients with confirmed COVID-19. PLoS ONE. 2021;16(3): e0248358.CrossRefPubMedPubMedCentral Kheir M, Saleem F, Wang C, Mann A, Chua J. Higher albumin levels on admission predict better prognosis in patients with confirmed COVID-19. PLoS ONE. 2021;16(3): e0248358.CrossRefPubMedPubMedCentral
22.
23.
go back to reference Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, MOVe-OUT Study Group, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509–20.CrossRefPubMed Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, MOVe-OUT Study Group, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509–20.CrossRefPubMed
24.
go back to reference Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, EPIC-HR Investigators, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397–408.CrossRefPubMed Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, EPIC-HR Investigators, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397–408.CrossRefPubMed
25.
go back to reference Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, COMET-ICE Investigators, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941–50.CrossRefPubMed Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, COMET-ICE Investigators, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941–50.CrossRefPubMed
26.
go back to reference O’Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, COVID-19 Phase 3 Prevention Trial Team, et al. Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial. JAMA. 2022;327:432–41 (Erratum in: JAMA. 2022;327:2024).CrossRefPubMed O’Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, COVID-19 Phase 3 Prevention Trial Team, et al. Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial. JAMA. 2022;327:432–41 (Erratum in: JAMA. 2022;327:2024).CrossRefPubMed
27.
go back to reference Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, Áinle FN, RAPID trial investigators, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021;375:n2400.CrossRefPubMed Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, Áinle FN, RAPID trial investigators, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021;375:n2400.CrossRefPubMed
28.
go back to reference Narita K, Nakaji S, Tabata R, Terao T, Kuzume A, Tsushima T, et al. Antibody response to COVID-19 vaccination in patients with lymphoma. Int J Hematol. 2022;115:728–36.CrossRefPubMedPubMedCentral Narita K, Nakaji S, Tabata R, Terao T, Kuzume A, Tsushima T, et al. Antibody response to COVID-19 vaccination in patients with lymphoma. Int J Hematol. 2022;115:728–36.CrossRefPubMedPubMedCentral
29.
go back to reference Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, PROVENT Study Group, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022;386:2188–200.CrossRefPubMed Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, PROVENT Study Group, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022;386:2188–200.CrossRefPubMed
Metadata
Title
Characteristics and prognosis of patients with COVID-19 and hematological diseases in Japan: a cross-sectional study
Authors
Daisuke Minakata
Tomoyuki Uchida
Aya Nakano
Ken Takase
Nodoka Tsukada
Hiroshi Kosugi
Eri Kawata
Takahiko Nakane
Hiroyuki Takahashi
Tomoyuki Endo
Satoshi Nishiwaki
Hideaki Fujiwara
Akiko M. Saito
Toshiki I. Saito
Koichi Akashi
Itaru Matsumura
Kinuko Mitani
Publication date
03-01-2024
Publisher
Springer Nature Singapore
Published in
International Journal of Hematology / Issue 2/2024
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-023-03685-w

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now